Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534831 | 0.97 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1KMT2AALDH1A1 | |
| SCHEMBL13314811 | 0.97 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1KMT2AALDH1A1 | |
| Formic Acid SCHEMBL3603162 | 0.83 | RAB9A (0.44) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3533425 | 0.81 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL13314816 | 0.81 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL13314812 | 0.79 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3538338 | 0.79 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3537545 | 0.78 | PDK1 (0.56) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| Formic Acid SCHEMBL3537527 | 0.78 | GAA (0.35) | KMT2A | |
| SCHEMBL13314817 | 0.77 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | RAB9A 4051/4885SMN1; SMN2 399/4885NPC1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.